Eton Pharmaceuticals, Inc. Quarterly Operating Income (Loss) in USD from Q3 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Eton Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2017 to Q3 2024.
  • Eton Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was $509K.
  • Eton Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$5.22M, a 380% decline year-over-year.
  • Eton Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$1.19M, a 85.6% increase from 2022.
  • Eton Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$8.26M, a 453% decline from 2021.
  • Eton Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$1.5M, a 94.5% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$5.22M $509K +$1.06M Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$6.28M -$2.94M -$6.82M -176% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $542K -$800K +$1.73M +68.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$1.19M -$1.99M -$3.06M -288% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 $1.86M -$548K +$2.35M +81.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$484K $3.88M +$5.22M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$5.71M -$2.53M +$2.55M +50.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$8.26M $1.06M -$252K -19.2% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 -$8.01M -$2.9M +$2.95M +50.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$11M -$1.34M +$985K +42.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$11.9M -$5.09M -$10.5M -195% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$1.5M $1.31M +$8.73M Oct 1, 2021 Dec 31, 2021 10-K 2024-03-14
Q3 2021 -$10.2M -$5.85M +$425K +6.78% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$10.7M -$2.33M +$2.21M +48.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$12.9M $5.36M +$14.2M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$27.1M -$7.42M -$4.76M -179% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-16
Q3 2020 -$22.3M -$6.27M -$1.23M -24.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-16
Q2 2020 -$21.1M -$4.54M -$1.19M -35.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 -$19.9M -$8.88M -$1.33M -17.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 -$18.6M -$2.66M -$370K -16.2% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-16
Q3 2019 -$18.2M -$5.04M -$2.67M -112% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$15.6M -$3.35M -$652K -24.2% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-12
Q1 2019 -$14.9M -$7.55M -$4.59M -155% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 -$10.3M -$2.29M Oct 1, 2018 Dec 31, 2018 10-K 2021-03-16
Q3 2018 -$2.37M +$396K +14.3% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$2.7M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 -$2.96M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q3 2017 -$2.77M Jul 1, 2017 Sep 30, 2017 10-Q 2018-12-20
* An asterisk sign (*) next to the value indicates that the value is likely invalid.